Status and progress in the treatment for locally resectable progressive gastric cancer and metastatic gastric cancer.
10.11817/j.issn.1672-7347.2020.190079
- Author:
Xiaofeng LIAO
1
;
Heli LIU
2
;
Peng LIU
3
Author Information
1. Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha 410008. 1757066296@qq.com.
2. Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha 410008. heliliu@csu.edu.cn.
3. Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha 410008.
- Publication Type:Journal Article
- Keywords:
advanced gastric cancer;
metastatic gastric cancer;
progressive gastric cancer
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Gastrectomy;
Humans;
Neoadjuvant Therapy;
Splenic Neoplasms;
Stomach Neoplasms;
drug therapy
- From:
Journal of Central South University(Medical Sciences)
2020;45(4):426-434
- CountryChina
- Language:English
-
Abstract:
For resectable gastric cancer, although radical surgery is still the main treatment, methods of operation and the curative effect of operation are still in the stage of exploration for metastatic gastric cancer. Radiotherapy, chemotherapy and molecular targeted therapy also play an important role in prolonging the survival period of patients with gastric cancer. Postoperative radiotherapy and chemotherapy can prolong the survival time, but for patients with locally advanced gastric cancer, the preoperative radiotherapy and chemotherapy can also further improve the survival period of patients compared with direct operation. In addition, with the development and using of molecular targeted drugs, such as antiangiogenic agents, immunosuppressive drugs and so on, the survival period of patients with gastric cancer has been further extended.
